CDR-Life Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

CDR-Life Inc. - overview

Established

2017

Location

Zurich, -, Switzerland

Primary Industry

Biotechnology

About

Based in Zürich, Switzerland, and founded in 2017 by Christian Leisner (CEO), CDR-Life Inc. is a biotechnology company that develops antibody technology, to target cancer-specific intracellular proteins. In April 2022, CDR-Life Inc. raised USD 76 million in series A funding co-led by new investors Jeito Capital and RA Capital Management, with participation from another new investor Omega Funds.


The company’s investors include RACAPITAL, Jeito, and Omega Funds. The firm has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. The company’s dual-MHC binding molecule format based on antibody fragments has the capability of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. The company’s few programs include CDR404 which is the most advanced program of the company for solid tumors, CDR101 is a trispecific next-generation BCMA targeting therapy for the treatment of relapsed/refractory multiple myeloma (RRMM), and many others.


The company will use the April 2022 funding for the clinical trials of CDR404 and develop further its novel targeted immunotherapies based on CDR-Life’s superior T cell engaging platform.


Current Investors

Omega Funds, RA Capital Management, Jeito Capital

Primary Industry

Biotechnology

Sub Industries

Biotechnology, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.cdr-life.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.